"Promising Experimental Drug Shows Potential for Treating Fatty Liver Disease in Obese Individuals"

An experimental weight loss drug called retatrutide has shown promise in improving liver health in obese individuals with fatty liver disease, according to a study led by Virginia Commonwealth University. The injectable drug reduced fat in the liver to the extent that participants would no longer be classified as having fatty liver disease. The findings suggest that retatrutide could potentially prevent or reverse liver disease in at-risk patients. Fatty liver disease affects millions of people in the US and can lead to liver failure and liver cancer. The drug is currently undergoing Phase 3 clinical trials.